CA1341253C - Ifn-.beta.2/il-6 humaine, sa purification et son utilisation - Google Patents

Ifn-.beta.2/il-6 humaine, sa purification et son utilisation

Info

Publication number
CA1341253C
CA1341253C CA000617131A CA617131A CA1341253C CA 1341253 C CA1341253 C CA 1341253C CA 000617131 A CA000617131 A CA 000617131A CA 617131 A CA617131 A CA 617131A CA 1341253 C CA1341253 C CA 1341253C
Authority
CA
Canada
Prior art keywords
ifn
beta
cells
monoclonal antibody
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000617131A
Other languages
English (en)
Inventor
Michel Revel
Menachem Rubinstein
Yves Mory
Louise Chen
Daniela Novick
Rita Michalevicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL85204A external-priority patent/IL85204A0/xx
Priority claimed from IL8837588A external-priority patent/IL88375A/en
Priority claimed from IL88376A external-priority patent/IL88376A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Priority to CA000617131A priority Critical patent/CA1341253C/fr
Application granted granted Critical
Publication of CA1341253C publication Critical patent/CA1341253C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA000617131A 1988-01-26 1989-01-24 Ifn-.beta.2/il-6 humaine, sa purification et son utilisation Expired - Fee Related CA1341253C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000617131A CA1341253C (fr) 1988-01-26 1989-01-24 Ifn-.beta.2/il-6 humaine, sa purification et son utilisation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IL85204A IL85204A0 (en) 1988-01-26 1988-01-26 Recombinant human interferon beta2,its preparation and pharmaceutical compositions comprising it
US19358088A 1988-05-13 1988-05-13
IL8837588A IL88375A (en) 1988-11-14 1988-11-14 Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
IL88376A IL88376A0 (en) 1988-11-14 1988-11-14 Pharmaceutical compositions containing interferon-beta 2
CA000617131A CA1341253C (fr) 1988-01-26 1989-01-24 Ifn-.beta.2/il-6 humaine, sa purification et son utilisation

Publications (1)

Publication Number Publication Date
CA1341253C true CA1341253C (fr) 2001-06-12

Family

ID=27508380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000617131A Expired - Fee Related CA1341253C (fr) 1988-01-26 1989-01-24 Ifn-.beta.2/il-6 humaine, sa purification et son utilisation

Country Status (1)

Country Link
CA (1) CA1341253C (fr)

Similar Documents

Publication Publication Date Title
EP0326120B1 (fr) IFN-bêta2/IL-6 humain, sa purification et ses utilisations
EP0790255B1 (fr) Anticorps monoclonaux dirigés contre le facteur de maturation de lymphocyte cytotoxique
US5011778A (en) Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
Nicola Granulocyte colony-stimulating factor and differentiation-induction in myeloid leukemic cells
US5808008A (en) Method of producing human pluripotent hematopoietic colony stimulating factor
IL88375A (en) Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
EP0275598B1 (fr) Clonage et expression moléculaire de IL-3 humain
AU1057788A (en) Molecular cloning and expression of human il-3
US5895646A (en) Isolated native primate GM-CSF protein
US5428012A (en) Oncostatin M and novel compositions having anti-neoplastic activity
Moore G‐CSF: Its relationship to leukemia differentiation‐inducing activity and other hemopoietic regulators
AU626791B2 (en) Oncostatin m and novel compositions having anti-neoplastic activity
RU2082756C1 (ru) Способ увеличения числа нейтрофилов у млекопитающего или человека, способ лечения миелоидной и моноцитоидной лейкемии у млекопитающих, способ индуцирования созревания незрелых миелоидных или моноцитоирных клеток у млекопитающих, способ очистки раствора активного человеческого интерлейкина
CA1340296C (fr) Facteur de regulation de la croissance cellulaire
Deryugina et al. Identification of a growth factor for primary murine stroma as macrophage colony-stimulating factor
AU651139B2 (en) Human IFN-beta 2/IL-6, its purification and use
EP0516845B1 (fr) Nouveau facteur de stimulation de colonies megakaryocytiques et procede de preparation
Taniguchi et al. Inhibition against CFU-C and CFU-E colony formation by soluble factor (s) derived from hairy cells
Specchia et al. Constitutive expression of IL‐1β, M‐CSF and c‐fms during the myeloid blastic phase of chronic myelogenous leukaemia
US5451506A (en) Oncostatin M and novel compositions having anti-neoplastic activity
US5304637A (en) Expression and purification of human interleukin-3 and muteins thereof
EP0833656A2 (fr) Compositions parmaceutiques comprenant de la restrictine p/activine a, et leur utilisation en qualite d'antagonistes de il-6 et/ou il-11
WO1991000907A1 (fr) Proteines chimiotactiques monocytes et peptides associes
CA1340266C (fr) Facteur hematopoietique pluripotentiel humain, stimulant les colonies; methode de preparation et utilisation
Arima et al. Interleukin 2 acts directly on a Tac-positive cloned B cell line established from a patient with adult T cell leukemia.

Legal Events

Date Code Title Description
MKLA Lapsed

Effective date: 20180612